Concord Biotech Limited (NSE: CONCORDBIO)
1,835.90
-17.80 (-0.96%)
Sep 6, 2024, 3:30 PM IST
Concord Biotech Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Cash & Equivalents | - | 151.42 | 34.99 | 6.67 | 51.44 | 24.08 |
Short-Term Investments | - | 228.22 | 305.8 | 872.5 | 550 | - |
Trading Asset Securities | - | 2,437 | 1,369 | 734.73 | 1,410 | 1,981 |
Cash & Short-Term Investments | 2,817 | 2,817 | 1,710 | 1,614 | 2,011 | 2,005 |
Cash Growth | 64.71% | 64.71% | 5.96% | -19.76% | 0.31% | - |
Accounts Receivable | - | 3,496 | 2,738 | 2,322 | 1,775 | 1,835 |
Other Receivables | - | 159.99 | 217.95 | 272.74 | 358.19 | 133.64 |
Receivables | - | 3,656 | 2,956 | 2,594 | 2,133 | 1,969 |
Inventory | - | 2,080 | 2,123 | 1,951 | 1,536 | 1,112 |
Prepaid Expenses | - | 73.31 | 55.19 | 47.61 | 45.44 | 40.23 |
Other Current Assets | - | 336.73 | 433.05 | 119.5 | 345.27 | 259.47 |
Total Current Assets | - | 8,962 | 7,277 | 6,327 | 6,071 | 5,386 |
Property, Plant & Equipment | - | 7,865 | 7,655 | 6,436 | 5,577 | 3,809 |
Long-Term Investments | - | 20.7 | 79.25 | 2.56 | 3.66 | 8.15 |
Other Intangible Assets | - | 3.2 | 1.98 | 35.77 | 64.18 | 0.93 |
Other Long-Term Assets | - | 156.1 | 126.8 | 327.4 | 108.69 | 201.1 |
Total Assets | - | 17,007 | 15,140 | 13,128 | 11,825 | 9,405 |
Accounts Payable | - | 944.35 | 938 | 831.06 | 463.97 | 712.33 |
Accrued Expenses | - | 168.21 | 146.19 | 131.45 | 102.38 | 75.61 |
Short-Term Debt | - | - | - | 43.37 | 50.99 | - |
Current Portion of Long-Term Debt | - | 62.3 | 250 | 250 | 250 | 125 |
Current Portion of Leases | - | 16.21 | 1.47 | 15.96 | 13.01 | 10.91 |
Current Income Taxes Payable | - | 54.94 | 89.99 | - | - | 17.82 |
Current Unearned Revenue | - | - | 13.13 | 32.72 | - | - |
Other Current Liabilities | - | 175.55 | 479.67 | 247.1 | 177.04 | 209.28 |
Total Current Liabilities | - | 1,422 | 1,918 | 1,552 | 1,057 | 1,151 |
Long-Term Debt | - | - | 62.36 | 312.49 | 562.5 | 355.28 |
Long-Term Leases | - | 18.87 | 1.64 | 3.11 | 16.33 | 29.35 |
Long-Term Deferred Tax Liabilities | - | 280.65 | 234.39 | 209.71 | 174.53 | 151.29 |
Other Long-Term Liabilities | - | 19.56 | 22.97 | 18.74 | 20.98 | 15.94 |
Total Liabilities | - | 1,741 | 2,240 | 2,096 | 1,832 | 1,703 |
Common Stock | - | 104.62 | 104.62 | 95.11 | 95.11 | 95.11 |
Additional Paid-In Capital | - | 819.71 | 819.71 | 829.22 | 829.22 | 829.22 |
Retained Earnings | - | 14,342 | 11,976 | 10,108 | 9,069 | 6,778 |
Shareholders' Equity | 15,266 | 15,266 | 12,900 | 11,032 | 9,994 | 7,702 |
Total Liabilities & Equity | - | 17,007 | 15,140 | 13,128 | 11,825 | 9,405 |
Total Debt | 97.38 | 97.38 | 315.46 | 624.93 | 892.83 | 520.54 |
Net Cash (Debt) | 2,719 | 2,719 | 1,395 | 988.98 | 1,118 | 1,485 |
Net Cash Growth | 94.98% | 94.98% | 41.02% | -11.58% | -24.66% | - |
Net Cash Per Share | 26.00 | 25.99 | 13.33 | 9.45 | 10.69 | 14.19 |
Filing Date Shares Outstanding | 104.55 | 104.62 | 104.62 | 104.62 | 104.62 | 104.62 |
Total Common Shares Outstanding | 104.55 | 104.62 | 104.62 | 104.62 | 104.62 | 104.62 |
Working Capital | - | 7,541 | 5,359 | 4,775 | 5,014 | 4,235 |
Book Value Per Share | 145.93 | 145.93 | 123.31 | 105.45 | 95.53 | 73.62 |
Tangible Book Value | 15,263 | 15,263 | 12,898 | 10,996 | 9,930 | 7,701 |
Tangible Book Value Per Share | 145.90 | 145.90 | 123.29 | 105.11 | 94.91 | 73.62 |
Land | - | 547.11 | 547.11 | 547.11 | 546.99 | 543.41 |
Buildings | - | 2,576 | 2,463 | 2,226 | 1,981 | 735.36 |
Machinery | - | 4,979 | 4,788 | 4,285 | 3,773 | 1,776 |
Construction In Progress | - | 2,115 | 1,727 | 741.55 | 179.46 | 1,414 |
Source: S&P Capital IQ. Standard template. Financial Sources.